Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort ascending | Description |
---|---|---|---|---|---|---|---|---|
POWDERED MILK THISTLE EXTRACT | COMPOSITION/Content of Silymarin | USP39–NF34 | 6764 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Row 2 of Column 2 of Table 1: Change 0 to: 85 AND Row 2 of Column 3 of Table 1: Change 0 to: 15 |
RINGER'S INJECTION | ASSAY | USP40–NF35 | 6019 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Calcium/Instrumental conditions/Mode: Change spectrophotometer to: spectrophotometry AND Line 1 of Potassium/Solution A: Change Suitable wetting agent to: Suitable nonionic wetting agent |
GLUCONOLACTONE | ASSAY/Procedure | USP40–NF35 | 4412 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Analysis: Change Each mL of Back-titrant to: Each milliliter of Titrant |
TIMOLOL MALEATE | IDENTIFICATION/B. | First Supplement to USP40–NF35 | 8416 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1: Change major peak of the Sample solution corresponds to that of the Standard solution, to: timolol peak of the Sample solution corresponds to that of the System suitability solution, |
MILK THISTLE CAPSULES | STRENGTH/Content of Silymarin | USP39–NF34 | 6765 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Row 2 of Column 2 of Table 1: Change 0 to: 85 AND Row 2 of Column 3 of Table 1: Change 0 to: 15 |
DESLORATADINE ORALLY DISINTEGRATING TABLETS | IMPURITIES/Organic Impurities | First Supplement to USP40–NF35 | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Sample solution: Change Add 70% of the flask volume of Mobile phase to: Add 70% of the flask volume of Diluent |
IOHEXOL | IMPURITIES/Limit of Free Iodide/Analysis | USP40–NF35 | 4649 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 3 of variable definition list: Change 0.1269 mg/mEq to: 126.9 mg/mEq |
TIMOLOL MALEATE | IMPURITIES/Enantiomeric Purity | First Supplement to USP40–NF35 | 8416 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 6 of Chromatographic system: Delete Autosampler temperature: 4° |
MILK THISTLE TABLETS | STRENGTH/Content of Silymarin | USP39–NF34 | 6767 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Row 2 of Column 2 of Table 1: Change 0 to: 85 AND Row 2 of Column 3 of Table 1: Change 0 to: 15 |
GRANISETRON HYDROCHLORIDE INJECTION | USP Reference standards <11> | First Supplement to USP40–NF35 | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 3 of USP Granisetron Related Compound C RS: Change carboxamide. to: carboxamide hydrochloride. |
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION | ASSAY/Procedure | USP40–NF35 | 5251 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 3 of Sample solution: Change 45-µm pore size. to: 0.45-µm pore size. |
DOBUTAMINE INJECTION | IDENTIFICATION/A. | USP39–NF34 | 3561 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Sample solution: Change 10 mg/mL of dobutamine hydrochloride in methanol, clarified by centrifugation to: Use the neat Injection. |
DOCETAXEL | IMPURITIES/Organic Impurities, Procedure 1 | Revision Bulletin (Official August 01, 2016) | Online | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Footnote c of Table 2: Change (2aR,4R,4aS,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4, 9,11,12,12b-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5,6-dione 12b… Read More |
MAGNESIUM ALUMINOMETASILICATE | ASSAY/Magnesium Oxide | USP39–NF34 | 7375 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Analysis: Change eriochrome black TS trituration to: eriochrome black T trituration |
GRANISETRON HYDROCHLORIDE TABLETS | USP Reference standards <11> | First Supplement to USP40–NF35 | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 3 of USP Granisetron Related Compound C RS: Change carboxamide. to: carboxamide hydrochloride. |
PHENYTOIN ORAL SUSPENSION | IMPURITIES/Organic Impurities | USP40–NF35 | 5690 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Sample solution: Change 1 mg/mL of Oral Suspension in Diluent to: Nominally 1 mg/mL of phenytoin prepared as follows. Weigh and transfer a suitable volume of Oral Suspension to an appropriate volumetric flask. Add methanol to about 20% of the final flask volume… Read More |
EZETIMIBE | IMPURITIES/Organic Impurities, Procedure 1/System suitability/Suitability requirements | USP39–NF34 | 3840 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 2 of Resolution: Change Standard solution to: System suitability solution |
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | First Supplement to USP39–NF34 | 8101 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Change Buffer, Mobile phase, Diluent, and Sample solution: Prepare as directed in the Assay. to: Buffer, Mobile phase, and Diluent: Prepare as directed in the Assay. AND Add Sample solution: Use the Sample… Read More |
ALMOTRIPTAN TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official February 01, 2017) | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 4 of USP Almotriptan Related Compound B RS: Change ½C4H4O to: ½C4H4O4 |
PIOGLITAZONE AND METFORMIN HYDROCHLORIDE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP40–NF35 | 5720 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 3 of Standard solution: Change USP Metformin Hydrochloride RS in Diluent A to: USP Metformin Hydrochloride RS from the Metformin standard stock solution in Diluent A |
MYCOPHENOLATE MOFETIL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4957 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of USP Mycophenolate Mofetil Related Compound A RS: Change C23H31NO7 to: C22H29NO7 |
REAGENTS, INDICATORS AND SOLUTIONS | Solutions/Volumetric Solutions | Second Supplement to USP39–NF34 | 8458 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 3 of 0.07 N Ferrous Ammonium Sulfate VS: Change In a 100-mL volumetric flask, to: In a 1000-mL volumetric flask, |
<127> FLOW CYTOMETRIC ENUMERATION OF CD34+ CELLS | SAMPLE PREPARATION/Table 1. Dot Plot Descriptions and Gating Instructions | USP40–NF35 | 216 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Column 4 for Step 6: Add • For counting bead enumeration, proceed to either Step 7 or Step 8 according to the recommendations of the bead manufacturer. |
POLYETHYLENE GLYCOL 3350 | SPECIFIC TESTS/Apparent Weight-Average Molecular Weight and Polydispersity | USP40–NF35 | 5745 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Standard solution: Change Standard solution: 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of 1000,2000, 3000, 4000, and 6000 g/mol (Da) in Mobilephase. Pass a portion of the solution to: Standard solutions: Prepare 1.0… Read More |
MYCOPHENOLATE MOFETIL FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4960 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Mycophenolate Mofetil Related Compound A RS: Change C23H31NO7 to: C22H29NO7 |
MAGNESIUM ALUMINUM SILICATE | SPECIFIC TESTS/Viscosity/Acceptance criteria | Second Supplement to USP39–NF34 | 8558 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Type IA: Change 225–600 to: 225–600mPa · s AND Line 1 of Type IB: Change 150–450 to: 150–450 mPa · s AND Line 1 of Type IC: Change 800–2200 to: 800–2200 mPa · s AND Line 1 of Type IIA: Change 100–300 to: … Read More |
NALTREXONE HYDROCHLORIDE | Related compounds | USP39–NF34 | 4985 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 5: Change 10F(C/W)(rU / rS) to: 1000F(C/W)(rU/rS) |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | TEST METHODS/Physicochemical Tests/Absorbance | USP39–NF34 | 493 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 3 of Plasticized polyvinyl chloride: Delete Additionally, for nonplasticized polyvinyl chloride materials only, determine the spectrum between 250 and 330 nm in the alcohol sample associated with Solution S6. |
TROSPIUM CHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 6287 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of USP Trospium Chloride Related Compound C RS:Change (1R,3r,5S)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1′-pyrrolidinium] chloride. to: (1R,3r,5S)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1′-pyrrolidinium] chloride, or (1R… Read More |
BACITRACIN ZINC | IMPURITIES | USP39–NF34 | 2674 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Delete the Residue on Ignition <281> test. |
NICOTINE POLACRILEX | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 5061 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Add USP Polacrilex Resin RS |
<711> DISSOLUTION | INTERPRETATION/Immediate-Release Dosage Forms/Immediate-Release Dosage Forms Pooled Sample | USP39–NF34 | 540 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Row 3 of Column 1 of Acceptance Table for a Pooled Sample: Change S1 to: S2 AND Row 4 of Column 1 of Acceptance Table for a Pooled Sample: Change S1 to: S3 |
CHONDROITIN SULFATE SODIUM, SHARK | IMPURITIES/Limit of Protein | USP39–NF34 | 6570 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 2 of Instrumental conditions: Change (See Spectrophotometry and Light-Scattering <851>.) to: (See Ultraviolet-Visible Spectroscopy <857>.) |
DIAZEPAM INJECTION | Assay | USP39–NF34 | 3445 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 7 of Procedure: 50C / V(RU / RS) to: 50(C / V)(RU / RS) |
OXANDROLONE TABLETS | Dissolution <711>/Test 3 | USP39–NF34 | 5193 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of Chromatographic system: Change 30-cm column to: 3-cm column |
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS | IMPURITIES/Organic Impurities | USP39–NF34 | 2895 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Row 3 of Column 1 of Table 6:Change Candesartan related compound Ab,c to: Candesartan cilexetil related compound Ab,c |
CHONDROITIN SULFATE SODIUM, SHARK | SPECIFIC TESTS/Clarity and Color of Solution | USP39–NF34 | 6570 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 2 of Instrumental conditions: Change (See Spectrophotometry and Light-Scattering <851>.) to: (See Ultraviolet-Visible Spectroscopy <857>.) |
DICLOFENAC SODIUM EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | USP39–NF34 | 3460 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 1 of Standard solution: Change 0.001 mg/mL of USP Diclofenac Sodium RS in Diluent to: 0.001 mg/mL each of USP Diclofenac Sodium RS and USP Diclofenac Related Compound A RS in Diluent |
<671> CONTAINERS--PERFORMANCE TESTING | MOISTURE VAPOR TRANSMISSION/Packaging System Classification for Multiple-Unit Containers and Unit-Dose Containers for Liquid Oral Dosage Forms/Procedure | USP38–NF33 | 465 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 1 of the Equation: Change [(W1i − WT) − (W14i − WT) − (WC1 − WC14)] × 365 × {[100/(W1i − WT)] × 14} to: [(W1i − W… Read More |
PALIPERIDONE | CHEMICAL INFORMATION | USP39–NF34 | 5253 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 5: Change (9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido [1,2-a]pyrimidin-4-one to: (9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-… Read More |
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION | ASSAY/Procedure | USP39–NF34 | 3529 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 1 of System suitability solution:Change USP Diphenhydramine Hydrochloride Related Compound A RS to: USP Diphenhydramine Related Compound A RS AND Line 4 of System suitability: Change for diphenhydramine hydrochloride related compound A and diphenhydramine… Read More |
CHONDROITIN SULFATE SODIUM, SHARK | COMPOSITION/Disaccharide Composition | USP39–NF34 | 6570 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 2 of Chondroitinase ABC solution: Change 10.0 mL of Buffer solution to: 1.0 mL of Buffer solution AND Line 4 of Analysis: Change and 1.0 mL to: and 0.1 mL |
IMIQUIMOD CREAM | IMPURITIES/Organic Impurities | USP39–NF34 | 4289 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Row 2 of Column 3 of Table 2: Change 1.5 to: 1.15 AND Row 3 of Column 3 of Table 2: Change 1.15 to: 1.5 |
ARGININE HYDROCHLORIDE | SPECIFIC TESTS/Chloride Content | USP38–NF33 | 2279 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Delete the subsection Blank: 140 mL of water and 1 mL of dichlorofluorescein TS AND The equation in the Analysis: Change Result = [(V − B) × N × F × 100]/W to: Result = (V × N × F × 100)/W AND Line… Read More |
PALIPERIDONE | IMPURITIES/Organic Impurities/System suitability/Suitability requirements | USP39–NF34 | 5253 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of Resolution: Change hydroxybenzyl to: hydroxybenzoyl |
FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER | ASSAY/Procedure | USP39–NF34 | 4020 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 3 of System suitability: Change for salmeterol and fluticasone propionate are to: for fluticasone propionate and salmeterol are |
VINPOCETINE | IMPURITIES/Organic Impurities | USP39–NF34 | 6880 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Footnote a of Table 1: Change Ethyl (12RS,13aSR,13bSR)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). to: Ethyl (12S,13aS,13bS… Read More |
LORAZEPAM | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4618 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 3 of USP Lorazepam Related Compound B RS: Change C13H9ClNO to: C13H9Cl2NO |
SELENOMETHIONINE | CHEMICAL INFORMATION | USP38–NF33 | 6226 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Line 3: Change [1464-42-2] to: [3211-76-5] |
RANITIDINE INJECTION | USP Reference standards <11> | USP39–NF34 | 5670 | 27-May-2016 | 1-Jun-2016 | USP40–NF35 | USP40–NF35 | Line 2 of USP Ranitidine Related Compound C RS: Change N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine. to: N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}methyl)sulfinyl]ethyl}-N′-methyl-2-nitro-1,1-… Read More |